Mayer SA et al. - There was no significant difference among the three groups in the proportion of patients with poor clinical outcome. The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 µg of rFVIIa than in the placebo group.